

House \_\_\_\_\_ Amendment NO. \_\_\_\_\_

Offered By \_\_\_\_\_

1 AMEND House Committee Substitute for Senate Committee Substitute for Senate Bill No. 126,  
2 Page 7, Section 338.255, Line 3, by inserting after all of said line the following:

3 "338.321. 1. The "Missouri Oral Chemotherapy Parity Interim Committee" is hereby  
4 created to study the disparity in patient co-payments between orally and intravenously administered  
5 chemotherapies, the reasons for the disparity, and the patient benefits in establishing co-payment  
6 parity between oral and infused chemotherapy agents. The committee shall consider information on  
7 the costs or actuarial analysis associated with the delivery of patient oncology treatments. The  
8 conclusions of this study shall satisfy any statutorily required actuarial analysis.

9 2. The Missouri oral chemotherapy parity interim committee shall consist of the following  
10 members:

11 (1) Two members of the senate, appointed by the president pro tempore of the senate;

12 (2) Two members of the house of representatives, appointed by the speaker of the house of  
13 representatives;

14 (3) One member who is an oncologist or physician with expertise in the practice of oncology  
15 licensed in this state under chapter 334;

16 (4) One member who is an oncology nurse licensed in this state under chapter 335;

17 (5) One member who is a representative of a Missouri pharmacy benefit management  
18 company;

19 (6) One member from an organization representing licensed pharmacists in this state;

20 (7) One member from the business community representing businesses on health insurance  
21 issues;

22 (8) One member from an organization representing the leading research-based  
23 pharmaceutical and biotechnology companies;

24 (9) One patient advocate;

25 (10) One member from the organization representing a majority of hospitals in this state;

26 (11) One member from a health carrier as such term is defined under section 376.1350;

27 (12) One member from the organization representing a majority of health carriers in this  
28 state, as such term is defined under section 376.1350;

29 (13) One member from the Leukemia and Lymphoma Society; and

30 (14) The director of the department of insurance, financial institutions and professional  
31 registration, who shall chair the committee.

32 3. All members, except for the members from the general assembly, shall be appointed by  
33 the governor no later than September 1, 2013. The department of insurance, financial institutions  
34 and professional registration shall provide assistance to the committee.

35 4. No later than January 1, 2014, the committee shall submit a report to the governor, the  
36 speaker of the house of representatives, the president pro tempore of the senate, and the appropriate  
37 legislative committee of the general assembly regarding the results of the study and any legislative

Action Taken \_\_\_\_\_ Date \_\_\_\_\_

1 recommendations."; and

2

3 Further amend said bill by amending the title, enacting clause, and intersectional references  
4 accordingly.

5